Tumor protein 53 mutations and inherited cancer: Beyond Li-Fraumeni syndrome

Current Opinion in Oncology

Volumn 22, Issue 1, 2010, Pages 64-69

  Palmero, Edenir I ^a   Achatz, Maria Iw ^b   Ashton Prolla, Patricia ^c   Olivier, Magali ^a   Hainaut, Pierre ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b A C CAMARGO CANCER CENTER   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Cancer predisposition syndrome; Germline mutation; Li Fraumeni syndrome; TP53 mutation

Indexed keywords

TUMOR PROTEIN;

DNA MODIFICATION; FAMILIAL CANCER; GENE MUTATION; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; LI-FRAUMENI SYNDROME; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 73849107145     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328333bf00     Document Type: Review

References (48)

1. Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res 1988; 48:5358-5362.
2. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250:1233-1238.
3. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28:622-629.
4. Li FP, Fraumeni JF Jr. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst 1969; 43:1365-1373.
5. Li FP, Garber JE, Friend SH, et al. Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals. J Natl Cancer Inst 1992; 84:1156-1160.
6. Strong LC. General keynote: hereditary cancer - lessons from Li-Fraumeni syndrome. Gynecol Oncol 2003; 88 (1 Pt 2):S4-S7; discussion S11-S13.
7. Bougeard G, Sesboüé R, Baert-Desurmont S, et al. Molecular basis of the Li- Fraumeni syndrome: an update from the French LFS families. J Med Genet 2008; 45:535-538.
8. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li-Fraumeni syndrome: clinical characteristics of families with TP53 germline mutations. J Clin Oncol 2009; 27:1250-1256.
9. Olivier M, Eeles R, Hollstein M, et al. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002; 19:607-614.
10. Krutilkova V, Trkova M, Fleitz J, et al. Identification of five new families strenghtens the link between childhood choroid plexus carcinoma and germline TP53 mutations. Eur J Cancer 2005; 41:1597-1603.
11. Birch JM, Alston RD, McNally RJ, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 2001; 20:4621-4628.
12. Nichols NM, Matthews KS. p53 unfolding detected by CD but not by tryptophan fluorescence. Biochem Biophys Res Commun 2001; 288: 111-115.
13. Wong P, Verselis SJ, Garber JE, et al. Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology 2006; 130:73-79.
14. Parkin DM, Whelan SL, Feraly J, et al., editors. Cancer incidence in five continents. Vol VII. Lyon: IARC Scientific Publications, No.143, IARC; 1997.
15. Srivastava S, Zou ZQ, Pirollo K, et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 348:747-749.
16. Bougeard G, Brugières L, Chompret A, et al. Screening for TP53 rearrangements in families with the Li-Fraumeni syndrome reveals a complete deletion of the TP53 gene. Oncogene 2003; 22:840-846.
17. Schiffman JD, Chun N, Fisher PG, et al. Identification of a novel p53 in-frame deletion in a Li-Fraumeni-like family. Pediatr Blood Cancer 2008; 50:914-916.
18. Bell DW, Varley JM, Szydlo TE, et al. Heterozygous germlinehCHK2 mutations in Li-Fraumeni syndrome. Science 1999; 286:2528-2531.
19. Vahteristo P, Tamminen A, Karvinen P, et al. p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition. Cancer Res 2001; 61:5718-5722.
20. Weischer M, Bojesen SE, Ellervik C, et al. CHEK2 1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol 2008; 26:542-548.
21. Strong LC, Williams WR, Tainsky MA. The Li-Fraumeni syndrome: from clinical epidemiology to molecular genetics. Am J Epidemiol 1992; 135: 190-199.
22. Birch JM, Blair V, Kelsey AM, et al. Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene 1998; 17:1061-1068.
23. Hisada M, Garber JE, Fung CY, et al. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998; 90:606-611.
24. Lalloo F, Varley J, Ellis D, et al. Prediction of pathogenic mutations in patients with early-onset breast cancer by family history. Lancet 2003; 361:1101-1102.
25. Ribeiro RC, Sandrini F, Figueiredo B, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A 2001; 98:9330-9335.
26. Figueiredo BC, Sandrini R, Zambetti GP, et al. Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet 2006; 43:91-96.
27. Achatz MI, Olivier M, Le Calvez F, et al. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett 2007; 245:96-102.
28. Garritano S, Gemignani F, Palmero EI, et al. High frequency of cancerpredisposing TP53 mutation p.R337H in the population of southern Brazil: evidence for a founder effect. Hum Mutat (in press).
29. Assumpcao JG, Seidinger AL, Mastellaro MJ, et al. Association of the germline R337H mutation with breast cancer in southern Brazil. BMC Cancer 2008; 8:357.
30. Palmero EI, Schuler-Faccini L, CaleffiM, et al. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in southern Brazil. Cancer Lett 2008; 261:21-25.
31. Di Giammarino EL, Lee AS, Cadwell C, et al. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol 2002; 1:12-16.
32. Trkova M, Hladikova M, Kasal P, et al. Is there anticipation in the age at onset in families with Li-Fraumeni syndrome? J Hum Genet 2002; 47:381-386.
33. Tabori U, Malkin D. Risk stratification in cancer predisposition syndromes: lessons learned from novel molecular developments in Li-Fraumeni syndrome. Cancer Res 2008; 68:2053-2057.
34. Trkova M, Prochazkova K, Krutilkova V, et al. Telomere length in peripheral blood cells of germline TP53 mutation carriers in shorter than that of normal individuals of corresponding age. Cancer 2007; 110:694-702.
35. Tabori U, Nanda S, Druker H, et al. Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. Cancer Res 2007; 67:1415-1418.
36. Shlien A, Tabori U, Marshall CR, et al. Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome. Proc Natl Acad Sci U S A 2008; 105:11264-11269.
37. Petitjean A, Achatz MI, Borresen-Dale AL, et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26:2157-2165.
38. Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003; 63:6643-6650.
39. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004; 119:591-602.
40. Bougeard G, Baert-Desurmont S, Tournier I, et al. Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 2006; 3:531-533.
41. Ruijs MW, Scmidt MK, Nevanlinna H, et al. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet 2007; 15:110-114.
42. Marcel V, Palmero EI, Falagan-Lotsch P, et al. TP53 PIN3 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. J Med Genet 2009 [Epub ahead of print].
43. Lazar V, Hazard F, Bertin F, et al. Simple sequence repeat polymorphism within the p53 gene. Oncogene 1993; 8:1703-1705.
44. Pleasants LM, Hansen MF. Identification of a polymorphism in intron 2 of the p53 gene. Hum Genet 1994; 93:607-608.
45. Thomas M, Kalita A, Labrecque S, et al. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999; 19:1092-1100.
46. Dumont P, Leu JI, Della Pietra AC 3rd, et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33:357-365.
47. Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer 2009; 9:95-107.
48. Gemignani F, Moreno V, Landi S, et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 2004; 23:1954-1956.